Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Organon & Co.
OGN
$13.70
Name : Organon & Co.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $3,597,749,248.00
EPSttm : 0.78
finviz dynamic chart for OGN
Organon & Co.
$13.70
0.15%
$0.02
OGN — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

6.42

Margin Of Safety %

32

Put/Call OI Ratio

1.06

EPS Next Q Diff

-0.2

EPS Last/This Y

2.9

EPS This/Next Y

0.02

Price

13.69

Target Price

14

Analyst Recom

3

Performance Q

2.2

Upside

25.3%

Beta

1.51

Ticker: OGN




21 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-20OGN13.491.020.09120684
2026-07-21OGN13.521.020.01120650
2026-07-22OGN13.521.021.00120562
2026-07-23OGN13.561.0225.00120561
2026-07-24OGN13.521.02999.99120612
2026-07-27OGN13.541.020.56120649
2026-07-28OGN13.521.020.00120746
2026-07-29OGN13.551.020.52120740
2026-07-30OGN13.551.020.01120762
2026-07-31OGN13.561.021.67120990
2026-08-03OGN13.561.020.88120998
2026-08-04OGN13.561.021.97121040
2026-08-05OGN13.571.028.57121202
2026-08-06OGN13.541.021.06121253
2026-08-07OGN13.611.022.27121353
2026-08-10OGN13.621.020.85121387
2026-08-11OGN13.651.030.02121438
2026-08-12OGN13.651.060.22119788
2026-08-13OGN13.721.060.87119269
2026-08-14OGN13.721.063.49118927
2026-08-17OGN13.71.063.49118927
DateSymbolLatestP/C OIP/C VolTotal OI
21 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-20OGN13.507.0- 3.62
2026-07-21OGN13.517.0- 3.62
2026-07-22OGN13.537.0- 3.62
2026-07-23OGN13.567.0- 3.62
2026-07-24OGN13.527.0- 3.62
2026-07-27OGN13.537.0- 3.62
2026-07-28OGN13.527.0- 3.62
2026-07-29OGN13.557.0- 3.62
2026-07-30OGN13.547.0- 3.62
2026-07-31OGN13.557.0- 3.62
2026-08-03OGN13.567.0- 3.62
2026-08-04OGN13.567.0- 3.62
2026-08-05OGN13.573.7- 3.62
2026-08-06OGN13.543.7- 3.62
2026-08-07OGN13.613.7- 3.62
2026-08-13OGN13.723.7- 3.62
2026-08-14OGN13.723.7- 3.62
2026-08-17OGN13.693.7- 3.62
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-20OGN2.80-0.636.53
2026-07-21OGN2.80-0.636.53
2026-07-22OGN2.80-0.636.53
2026-07-23OGN2.80-0.636.53
2026-07-24OGN2.80-0.636.53
2026-07-27OGN2.80-0.466.21
2026-07-28OGN2.80-0.466.21
2026-07-29OGN2.80-0.466.21
2026-07-30OGN2.80-0.466.21
2026-07-31OGN2.80-0.466.21
2026-08-03OGN2.800.326.21
2026-08-04OGN2.800.326.21
2026-08-06OGN1.220.326.21
2026-08-07OGN1.220.326.21
2026-08-10OGN1.250.526.21
2026-08-11OGN1.250.526.21
2026-08-12OGN1.250.526.42
2026-08-13OGN1.250.526.42
2026-08-14OGN1.250.526.42
2026-08-17OGN1.250.206.42
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.85

Avg. EPS Est. Current Quarter

1.05

Avg. EPS Est. Next Quarter

0.66

Insider Transactions

1.25

Institutional Transactions

0.2

Beta

1.51

Average Sales Estimate Current Quarter

1568

Average Sales Estimate Next Quarter

1532

Fair Value

18.05

Quality Score

62

Growth Score

56

Sentiment Score

98

Actual DrawDown %

65.3

Max Drawdown 5-Year %

-82.7

Target Price

14

P/E

17.54

Forward P/E

3.63

PEG

0.9

P/S

0.59

P/B

3.57

P/Free Cash Flow

6.34

EPS

0.78

Average EPS Est. Cur. Y​

3.62

EPS Next Y. (Est.)

3.64

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.41

Relative Volume

0.75

Return on Equity vs Sector %

-5.6

Return on Equity vs Industry %

-15.1

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.18

EBIT Estimation

OGN Healthcare
$13.69
📉
Swing / Pullback
Buy the dip on strong trends
25 /100
WEAK
Trend
0/20
Pullback
0/25
Volume
9/15
Valuation
11/20
TP/AR
2/10
Options
3/10
RSI
71.1
Range 1M
89.1%
🚀
Momentum Growth
Ride accelerating trends
N/A
18 /100
WEAK
Momentum
6/25
Growth
2/30
Estimates
5/20
Inst/Vol
4/15
Options
1/10
EPS Yr
-3.8%
EPS NY
7.1%
52W%
99.7%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +252.5% upside
Quality
12/30
Valuation
28/30
Growth
4/25
Stability
6/10
LT Trend
1/5
Upside
+252.5%
Quality
62
MoS
32%
OGN — P/E HistoricalDrug Manufacturers - General
Organon & Co.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 10000
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
OGN

Latest News

Caricamento notizie per OGN
stock quote shares OGN – Organon & Co. Stock Price stock today
news today OGN – Organon & Co. stock forecast ,stock prediction 2023 2024 2025
marketwatch OGN – Organon & Co. yahoo finance google finance
stock history OGN – Organon & Co. invest stock market
stock prices OGN premarket after hours
ticker OGN fair value insiders trading